Author Index to Volume 21

Abbott RM. *See* Joyce PR
Addy RO, Foliart RH, Saran AS, Schubert DSP. EEG observations during combined haloperidol–lithium treatment, 170
Adinoff B, Majchrowicz E, Martin PR, Linnoila M. The benzodiazepine antagonist Ro 15-1788 does not antagonize the ethanol withdrawal syndrome, 643
Adler LE, Rose G, Freedman R. Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol, 787
Advokat C. *See* Schlemmer RF Jr
Agarwal AK. *See* Sethi BB
Agras WS. *See* Roth WT
Ainslie J. *See* McMahon T
Alarcon RD. *See* Smythies JR
Alcena V. *See* Young RC
Alcser K. *See* Kumar A
Alessi NE. *See* Dilsaver SC
Alexander DR, Deeb M, Bitar F, Antun F. Sodium-potassium, magnesium, and calcium ATPase activities in erythrocyte membranes from manic-depressive patients responding to lithium, 997
Alexander GJ. *See* Sechzer JA
Alföldi A. *See* Magyar I
Altamura AC, Bareggi SR, Invernizzi G, Morganti A, Zanchetti A. The effects of mianserin therapy on plasma renin activity in depressed patients, 1331
Alterman I. *See* Siever LJ
Altschule MD. Psychogenic polydipsia, 577-le
Ambrose MJ. *See* Simson PG
Amemiya M. *See* Hayashida Y
Anderson GM. *See* Riddle MA
Andreasen NC. *See* Nasrallah HA
Aneha S. *See* Matsue Y
Angel RW. *See* Malenka RC
Ansseau M. *See* Charles G
Ansseau M. *See* Legros JJ
Antun F. *See* Alexander DR
Appel D. *See* Oxenkrug GF
Arana GW. *See* Biederman J
Arató M. *See* Faludi G
Arató M. *See* Magyar I
Ardern M. *See* Kolakowska T
Asnis G. *See* Halbreich U
Asnis GM. *See* Lemus CZ
Atkinson JH Jr, Kremer EF, Risch SC, Dana R, Janowsky DS. Neuroendocrine responses in psychiatric and pain patients with major depression, 612
Avery D. *See* Khan A

Bachs JS. *See* Obiols JE
Bailine SH, Doft M. Neurotoxicity induced by combined lithium–thioridazine treatment, 834
Baldessarini RJ. *See* Biederman J
Ballantine HT Jr. *See* Black PM
Ballast CL, Sharp RR, Domino EF. Effect of lithium on RBC water permeability, 426-le
Balon R. *See* Oxenkrug GF
Banquet JP. *See* Guenther W
Bareggi SR. *See* Altamura AC
Barkai AI, Baron M, Kowalik S, Cooper TB. Modification of ligand binding to membranes by a soluble acceptor. Alpha-1-acid glycoprotein attenuates ^{3}H-imipramine binding to cerebral membranes, 883
Baron M. *See* Barkai AI
Baron M. Genetics of schizophrenia: I. Familial patterns and mode of inheritance, 1051
Baron M. Genetics of schizophrenia: II. Vulnerability traits and gene markers, 1189
Barthelemy C. *See* Martineau J
Baumgartner A. Central thyroid stimulation in severely ill depressed, manic and schizophrenic patients, 417
Beal MF. *See* Black PM
Benkelfat C. *See* Lôo H
Beresford TP, Blow FC, Hall RCW. AIDS encephalitis mimicking alcohol dementia and depression, 394
Berger M. *See* Höchli D
Berger PA. *See* Csernansky JG
Berger PA. *See* Malenka RC
Berrettini WH, Nurnberger JI Jr, Hare TA, Simmons-Alling S, Gershon ES. CSF GABA in euthymic manic-depressive patients and controls, 844

Abbreviations
ed: Editorial
le: Letter to the Editor

Beyer H. *See* Holsboer F
Bieber K. *See* Born J
Biederman J, Baldessarini RJ, Harmatz JS, Rivinus TM, Arana GW, Herzog DB, Schildkraut JJ. Heterogeneity in anorexia nervosa, 213
Bigelow LB. *See* Grebb JA
Bitar F. *See* Alexander DR
Black PM, Ballantine HT Jr, Carr DB, Beal MF, Martin JB. Beta-endorphin and somatostatin concentrations in the ventricular cerebrospinal fluid of patients with affective disorder, 1077
Blackwood DHR, Christie JE. The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia, 557
Blackwood DHR, St Clair DM, Kutcher SP. P300 event-related potential abnormalities in borderline personality disorder, 560
Bliwise DL. *See* Kaitin KI
Bloomingdale KL, Vasile RG, Gudeman JE, Gerson B, Schildkraut JJ. The dexamethasone suppression test (DST) and platelet monoamine oxidase (MAO) activity as predictors of psychosis in depression, 390
Blow FC. *See* Beresford TP
Bogerts B. *See* Roberts GW
Bøler JB. *See* Reichelt KL
Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, family history, and DST response: a pilot study, 1239
Born J, Kern W, Bieber K, Fehm-Wolfsdorf G, Schiebe M, Fehm HL. Night-time plasma cortisol secretion is associated with specific sleep stages, 1415
Bosmann HB. *See* Thienhaus OJ
Boutros NN, Hughes JR, Weiler M. Psychiatric correlates of rhythmic midtemporal discharges and 6/sec spike and wave complexes, 94
Bowcock SA. *See* Mooney NA
Braf DL. *See* Swerdlow NR
Breier A. *See* Wolkowitz OM
Breitling D. *See* Guenther W
Brenner RP. *See* Cornelius JR
Brewerton TD. Lithium counteracts carbamazepine-induced leukopenia while increasing its therapeutic effect, 677
Bridger WH. The fourth world congress of biological psychiatry, 123-ed
Bridges M, Yeragani VK, Rainey JM, Pohl R. Dexamethasone suppression test in patients with panic attacks, 853
Britton KT. *See* Downs NS
Brophy MH. Zinc and childhood hyperactivity, 704-le
Bruinvels J. *See* Fekkes D
Buckman TD. *See* Tachiki KH
Buell U. *See* Guenther W
Burrows GD. *See* McIntyre IM
Bush D. *See* Rothke S

Cameron O, Lee MA, Kotun J, Murphy ST. Circadian fluctuations in anxiety disorders, 567-le
Cantraine F. *See* Egrise D
Carey RJ. *See* Lynch MR
Carey RJ. Relationship of limbic dopamine levels to amphetamine- and anticholinergic- induced hyperactivity in the rat, 317
Carnoy P, Soubrie P, Puech AJ, Simon P. Performance deficit induced by low doses of dopamine agonists in rats. Toward a model for approaching the neurobiology of negative schizophrenic symptomatology, 11
Carr DB. *See* Black PM
Carr V, Morris H, Gilliland J. The effect of serum dexamethasone concentrations in the dexamethasone suppression test, 735
Chang HF. *See* Chang WH
Chang I. *See* Georgotas A
Chang WH, Yeh EK, Hu WH, Tseng YT, Chung MC, Chang HF. Acute and chronic effects of haloperidol on plasma and brain homovanillic acid in the rat, 374
Chang WH, Yeh EK, Hu WH, Tseng YT, Chung MC, Chang HF. Prefrontal cortex: possible site of antipsychotic action of haloperidol, 422
Chapman SM. *See* Nasrallah HA
Charles G, Ansseau M, Sulon J, Demey-Ponsart E, Meunier JC, Wilmotte J, Legros JJ. Free cortisol and the dexamethasone suppression test, 549
Charles G, LeFevre A, Mirel J. Barbiturates and DST, 860-le
Charles GA, Maes JM, Wilmotte J. DST and endogeneity, 119-le
Chiba H. *See* Matsue Y
Chouinard G, Steiner W. Remoxipride in the treatment of acute mania, 1429
Christie JE. *See* Blackwood DHR
Chung MC. *See* Chang WH
Cliffe C. *See* Thienhaus OJ
Clower CG. DST, ECT, and prognosis, 1353-le
Coffman JA. *See* Nasrallah HA
Cohen DJ. *See* Riddle MA
Cohen MR. *See* Wolkowitz OM
Cohen MR, Sailer V, McAmis B, Jenkins P. Superoxide dismutase activity in fibroblasts from patients with schizophrenia, 322
Cohen RM. *See* Newhouse PA
Coleman J. *See* Surman OS
Colter N. *See* Roberts GW

Conri C, Simonoff M, Fleury B, Moreau F. Does vanadium play a role in depressive states? 546
Conri C, Simonoff M, Fleury B, Moreau F. Variations in serum vanadium levels during the treatment of mental depression, 1335
Cook EH, Leventhal BL. Triiodothyronines, depression and fasting, 425-le
Cook N. *See* Thomas DR
Cooke ED. *See* Mooney NA
Cooper TB. *See* Barkai AI
Cooper TB. *See* Georgotas A
Cooper TB. *See* Nemes ZC
Coppen A. *See* Robertson MM
Cornelius JR, Brenner RP, Soloff PH, Schulz SC, Tumuluru RV. EEG abnormalities in borderline personality disorder: specific or nonspecific, 977
Cornelius JR, Soloff PH, Miewald BK. Behavioral manifestations of paraneoplastic encephalopathy, 686
Coryell W. *See* Pfohl B
Cowan RP. *See* Schneider LS
Cross CK. *See* Secunda SK
Crow TJ. *See* Patou G
Crow TJ. *See* Roberts GW
Csernansky CA. *See* Csernansky JG
Csernansky JG, Csernansky CA, King R, Hollister LE. Oscillations in apomorphine-induced stereotypes during 1 year of apomorphine administration, 402
Csernansky JG, Csernansky CA, Mellentin JD, Hollister LE. Carbamazepine and dopaminergic supersensitivity, 238-le
Csernansky JG, Prosser E, Kaplan J, Mahler E, Berger PA, Hollister LE. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics, 632
Csima A. *See* Williamson PC

Dager S. *See* Khan A
Dana R. *See* Atkinson JH Jr
Darwish AK. *See* El Sobky A
David JJ. *See* Vieweg WVR
Davies HD. *See* Peabody CA
Davies T. *See* El Sobky A
Davis J. *See* Lazarus LW
Davis JM. *See* Schlemmer RF Jr
Decina P. *See* Steif BL
Deeb M. *See* Alexander DR
Deicken RF. Captopril treatment of depression, 1425
Dekker DK. *See* Ford MR
Delaney MA. *See* Schmidt K
de Leon MJ. *See* London E
Dement WC. *See* Kaitin KI
Dement WC. *See* Welsh DK
Demey-Ponsart E. *See* Charles G
Denber HCB. The electrophysiology of schizophrenia, 233-le
Dennis T. *See* Lôo H
Dilsaver SC. Cholinergic-monoamine systems, depression, and panic, 571-le
Dilsaver SC. Pathophysiology of "cholinoceptor supersensitivity" in affective disorders, 813
Dilsaver SC, Snider RM, Alessi NE. Stress induces supersensitivity of a cholinergic system in rats, 1093
Direnfeld LK. *See* Zubenko GS
Doft M. *See* Bailine SH
Domino EF. *See* Ballast CL
Donald RA. *See* Joyce PR
Doran AR. *See* Wolkowitz OM
Douglass AB. *See* Wilson DWS
Downs NS, Britton KT, Gibbs DM, Koob GF, Swerdlow NR. Supersensitive endocrine response to physostigmine in dopamine-depleted rats: a model of depression? 775
Dunn VD. *See* Nasrallah HA
Dunner D. *See* Khan A

Eberhard G. *See* Mathé AA
Egrise D, Rubinstein M, Schoutens A, Cantraine F, Mendlewicz J. Seasonal variation of platelet serotonin uptake and ^{3}H-imipramine binding in normal and depressed subjects, 283
Ehrhardt JC. *See* Nasrallah HA
Eiduson S. *See* Tachiki KH
Eisenberg J. *See* Lemus CZ
El Shazly M. *See* El Sobky A
El Sobky A, El Shazly M, Darwish AK, Davies T, Griffin K, Keshavan MS. Hydergine effect on prolactin and reaction time in dementia, 1229-le
Endo J. *See* Endo M
Endo M. Pituitary function, affective disorder, and cerebellar vermis atrophy, 705-le
Endo M, Seno H, Haruki S, Ishino H, Endo J. Pituitary function and deep brain structures, 240-le
Englund E. *See* London E

Faludi G, Kaskó M, Perényi A, Arató M, Frecska E. The dexamethasone suppression test in panic disorder and major depressive episodes, 1008
Fehm HL. *See* Born J
Fehm-Wolfsdorf G. *See* Born J
Fein G. *See* Merrin EL

Fekkes D, Bruinvels J. Serine and folate metabolism in fibroblasts from episodic psychotic patients with psychedelic symptoms, 951
Ferris S. *See* London E
Fiedler P, Wolkin A, Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics, 1347
Flattery JJ. *See* Warner MD
Fleischmann RL. *See* Hirschowitz J
Fleury B. *See* Conri C
Floyd TC. *See* Merrin EL
Foliart RH. *See* Addy RO
Fontaine R. *See* Steiner W
Fontaine R. *See* Van Haren J
Ford MR, Goethe JW, Dekker DK. EEG coherence and power in the discrimination of psychiatric disorders and medication effects, 1175
Frances H, Simon P. The effect of a beta-adrenergic agonist on behaviors mediated by 5-HT1A and 5-HT1B receptors, 1075
Frecska E. *See* Faludi G
Freedman R. *See* Adler LE
Friedman E. *See* Georgotas A
Frohman CE. *See* Hryhorczuk LM
Fuentenebro F. *See* Irwin M
Fujiwara Y. *See* Kashihara K
Fukuda T. *See* Izumi K

Galin H. *See* Williamson PC
Gallen CC. *See* Roth WT
Galzin AM, Lôo H, Sechter D, Langer SZ. Lack of seasonal variation in platelet [^{3}H]imipramine binding in humans, 876
Gander PH. *See* Welsh DK
Garbutt JC. *See* Hsiao JK
Garreau M. *See* Lôo H
Garver DL. *See* Hirschowitz J
Gasparini F. *See* Halbreich U
Gattaz WF, Köllisch M. Bromocriptine in the treatment of neuroleptic-resistant schizophrenia, 519
Gentes C. *See* London E
George AE. *See* London E
Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, Chang I, Cooper TB. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly, 1155
Gerken A. *See* Holsboer F
Gershon ES. *See* Berrettini WH
Gershon ES. *See* Nurnberger JI Jr
Gershon S. *See* Yeragani VK
Gerson B. *See* Bloomingdale KL
Geyer MA. *See* Swerdlow NR
Ghadirian AM. Paradoxical mood response following antidepressant withdrawal, 1298
Gibbs DM. *See* Downs NS
Gierl B. *See* Lazarus LW
Giles DE, Roffwarg HP, Schlesser MA, Rush AJ. Which endogenous depressive symptoms relate to REM latency reduction? 473
Giles DE, Rush AJ, Roffwarg HP. Sleep parameters in bipolar I, bipolar II, and unipolar depressions, 1340
Gilliland J. *See* Carr V
Gillin JC. *See* Overstreet DH
Gitlin MJ. L-Triiodothyronine-precipitated angina and clinical response, 543
Gleason C. *See* Kaitin KI
Glotzbach RK. *See* Kent TA
Goethe JW. *See* Ford MR
Goldstein S. *See* Halbreich U
Goodin DS. P300 latency as a biological marker of dementia, 1111-ed
Gordon E, Kraiuhin C, Harris A, Meares R, Howson A. The differential diagnosis of dementia using P300 latency, 1123
Grebb JA, Shelton RC, Taylor EH, Bigelow LB. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia, 691
Greden JF. *See* Kumar A
Griffin K. *See* El Sobky A
Grimm W. *See* Holsboer F
Grob CS. Persistent supersensitivity vomiting following neuroleptic withdrawal in an adolescent, 398
Grochocinski VJ. *See* Kupfer DJ
Grof P. *See* Kraus RP
Groves L. *See* Lazarus LW
Growdon JH. Phosphatidylcholine and tardive dyskinesia, 702-le
Grunhaus L. *See* Kumar A
Gudeman JE. *See* Bloomingdale KL
Guenther W, Breitling D, Banquet JP, Marcie P, Rondot P. EEG mapping of left hemisphere dysfunction during motor performance in schizophrenia, 249
Guenther W, Moser E, Mueller-Spahn F, von Oefele K, Buell U, Hippius H. Pathological cerebral blood flow during motor function in schizophrenia and endogenous depressed patients, 889
Gulati A. *See* Sethi BB

Ha YS. *See* Lazarus LW
Halbreich U. *See* Lemus CZ

Halbreich U, Naor S, Asnis G, Gasparini F, Goldstein S, Vital-Herne J, Kang BJ. Decreased dexamethasone suppression in endogenously depressed patients with normal basal plasma levels of cortisol, 1434
Hall RCW. *See* Beresford TP
Hanada S. *See* Mita T
Hapworth W. *See* Georgotas A
Harada T. *See* Kashihara K
Harcherik DF. *See* Riddle MA
Hare T. *See* Siever LJ
Hare TA. *See* Berrettini WH
Hariharasubramanian N. *See* Nair NPV
Harmatz JS. *See* Biederman J
Harris A. *See* Gordon E
Harris B. *See* Thomas DR
Haruki S. *See* Endo M
Harvey KJ. *See* Kraus RP
Hatsukami DK, Mitchell JE, Morley JE, Morgan SF, Levine AS. Effect of naltrexone on mood and cognitive functioning among overweight men, 293
Hayashida Y, Mitani Y, Hosomi H, Amemiya M, Mifune K, Tomita S. Auditory brain stem responses in relation to the clinical symptoms of schizophrenia, 177
Heinze WJ. *See* Schlemmer RF Jr
Hermann BP. *See* Stone JL
Herzog DB. *See* Biederman J
Hines KG. *See* Renshaw PF
Hippius H. *See* Guenther W
Hirschowitz J, Zemlan FP, Hitzemann RJ, Fleischmann RL, Garver DL. Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems, 445
Hitzemann RJ. *See* Hirschowitz J
Höchli D, Riemann D, Zulley J, Berger M. Initial REM sleep suppression by clomipramine: a prognostic tool for treatment response in patients with a major depressive disorder, 1217
Hodgkinson J. Disney's "Return to Oz," and ECT, 578-le
Hodoba D. Paradoxic sleep facilitation by interictal epileptic activity of right temporal origin, 1267
Hoehn-Saric R. *See* McLeod DR
Hollister LE. *See* Csernansky JG
Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Müller OA, Stalla GK. Human corticotropin-releasing hormone in depression—correlation with thyrotropin secretion following thyrotropin-releasing hormone, 601
Hölzl G. *See* Krüger R
Hopwood SE. *See* Naylor GJ
Höschl C, Kozeny J. DST in Czechoslovakia, 1103-le
Hosomi H. *See* Hayashida Y
Hotta I, Yamawaki S. Lithium decreases 5-HT_1 receptors but increases 5-HT–sensitive adenylate cyclase activity in rat hippocampus, 1382
Howson A. *See* Gordon E
Hryhorczuk LM, Rainey JM Jr, Frohman CE, Novak EA. A new metabolic pathway for *N,N*-dimethyltryptamine, 84
Hsiao JK, Garbutt JC, Loosen PT, Mason GA, Prange AJ Jr. Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression? 595
Hu WH. *See* Chang WH
Hughes JR. *See* Boutros NN
Hughes JR. *See* Stone JL
Hullett J. *See* Tachiki KH
Hunt SA. *See* Mooney NA
Hux M. *See* Kraus RP
Hyde T. *See* Khan A

Iager AC, Kirch DG, Jeste DV, Wyatt RJ. Defect symptoms and abnormal involuntary movement in schizophrenia, 751
Igata A. *See* Izumi K
Ikeda M. *See* Tada K
Imamura K. *See* Izumi K
Invernizzi G. *See* Altamura AC
Iovino M. *See* Monteleone P
Irwin GH. *See* Kent TA
Irwin M, Fuentenebro F, Marder SR, Yuwiler A. L-5-Hydroxytryptophan-induced delirium, 673
Isaac I. *See* Nair NPV
Ishino H. *See* Endo M
Ishiwata H. *See* Tada K
Izumi K, Tominaga H, Koja T, Nomoto M, Shimizu T, Sonoda H, Imamura K, Igata A, Fukuda T. Meclofenoxate therapy in tardive dyskinesia: a preliminary report, 151
Izumiya Y. *See* Kiriike N

Jaeger J. *See* Nemes ZC
Jain AK. *See* Oxenkrug GF
Janowsky DS. *See* Atkinson JH Jr
Janowsky DS. *See* Overstreet DH
Jaswinder S. *See* Mukundan CR
Jauregui J. *See* Stinus L
Javaid JI. *See* Lazarus LW
Jefferys D. *See* McIntyre IM
Jenkins P. *See* Cohen MR
Jensen M. *See* Schmidt K

Jernajczyk W. Latency of eye movement and other REM sleep parameters in bipolar depression, 465
Jeste DV. *See* Iager AC
Jeste DV. *See* Kaufmann CA
Jeste DV. *See* Lohr JB
Jones KJ. *See* Surman OS
Joyce PR, Donald RA, Nicholls MG, Livesey JH, Abbott RM. Endocrine and behavioral responses to methylphenidate in normal subjects, 1015
Judd FK. *See* McIntyre IM

Kadlubovski M. *See* Kutcher SP
Kafka MS. *See* Kaufmann CA
Kaitin KI, Bliwise DL, Gleason C, Nino-Murcia G, Dement WC, Libet B. Sleep disturbance produced by electrical stimulation of the locus coeruleus in a human subject, 710
Kalin NH. ACTH in plasma and CSF in the rhesus monkey, 124
Kalivas PW, Richardson-Carlson R, Van Orden G. Cross-sensitization between foot shock stress and enkephalin-induced motor activity, 939
Kang BJ. *See* Halbreich U
Kaplan J. *See* Csernansky JG
Karoum F. *See* Roy A
Kashihara K, Sato M, Fujiwara Y, Harada T, Ogawa T, Otsuki S. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain, 650
Kaskó M. *See* Faludi G
Kathol RG. *See* Wysham C
Katz MM. *See* Secunda SK
Kaufmann CA, Jeste DV, Shelton RC, Linnoila M, Kafka MS, Wyatt RJ. Noradrenergic and neuroradiological abnormalities in tardive dyskinesia, 799
Kawakita Y. *See* Kiriike N
Kaye WH. *See* Uhde TW
Keenan S. *See* Welsh DK
Kelley AE. *See* Stinus L
Kemali D. *See* Kemali M
Kemali M, Milici N, Kemali D. Melatonin and LSD induce similar retinal changes in the frog, 981
Kent TA, Preskorn SH, Glotzbach RK, Irwin GH. Amitriptyline normalizes tetrabenazine-induced changes in cerebral microcirculation, 483
Kerkhofs M, Missa JN, Mendlewicz J. Sleep electroencephalographic measures in primary major depressive disorder: distinction between DST suppressor and nonsuppressor patients, 228
Kern W. *See* Born J
Keshavan MS. *See* El Sobky A
Kessler L. *See* Nurnberger JI Jr
Khan A, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner D. Platelet MAO-B activity in anxiety and depression, 847
Kim OM. *See* Georgotas A
King R. *See* Csernansky JG
Kirch DG. *See* Iager AC
Kiriike N, Nishiwaki S, Izumiya Y, Kawakita Y. Dexamethasone suppression test in bulimia, 328
Kleber HD. *See* Kosten TR
Kling AS. *See* Tachiki KH
Kocsis J. *See* Secunda SK
Koja T. *See* Izumi K
Kolakowska T, Williams AO, Ardern M, Reveley MA. Tardive dyskinesia in schizophrenics under 60 years of age, 161
Köllisch M. *See* Gattaz WF
Koob GF. *See* Downs NS
Koob GF. *See* Swerdlow NR
Kopell ML. *See* Roth WT
Koslow S. *See* Secunda SK
Kosten TR, Kreek MJ, Ragunath J, Kleber HD. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts, 217
Kotun J. *See* Cameron O
Kowalik S. *See* Barkai AI
Kozeny J. *See* Höschl C
Kraiuhin C. *See* Gordon E
Kraus RP, Grof P, Harvey KJ, Hux M. Methylene blue validates compliance (ingestion of dexamethasone) on the dexamethasone suppression test, 968
Kreek MJ. *See* Kosten TR
Kremer EF. *See* Atkinson JH Jr
Krüger R, Hölzl G, Kuss HJ, Schefold L. Influence of neuroleptics on the metabolism of tricyclic antidepressants—in vitro experiments with rat liver microsomes, 1247
Kumar A, Alcser K, Grunhaus L, Greden JF. Relationships of the dexamethasone suppression test to clinical severity and degree of melancholia, 436
Kumar P. *See* Sethi BB
Kuno T. *See* Mita T
Kupfer DJ. *See* Sewitch DE
Kupfer DJ, Reynolds CF III, Ulrich RF, Grochocinski VJ. Comparison of automated REM and slow-wave sleep analysis in young and middle-aged depressed subjects, 189
Kuss HJ. *See* Krüger R
Kutcher SP. *See* Blackwood DHR

Kutcher SP, Kadlubovski M. Are thyrotropin-binding inhibiting immunoglobulins associated with lithium-induced thyroid gland dysfunction? 414
Kwong LL. *See* Tecott LH

Laine DE. *See* Mitchell JE
Landis H. *See* Secunda SK
Langer SZ. *See* Galzin AM
Langlais PJ. *See* Zubenko GS
Lazarus LW, Groves L, Gierl B, Pandey G, Javaid JI, Lesser J, Ha YS, Davis J. Efficacy of phenelzine in geriatric depression, 699
Leander JD. Peripheral action of serotonin as a model of depression, 842
Leaton EM. *See* Levin R
Lee E. *See* Khan A
Lee MA. *See* Cameron O
Lee SI. *See* Levin R
LeFevre A. *See* Charles G
Legros JJ. *See* Charles G
Legros JJ, Ansseau M. Vasopressin–neurophysin and bipolar depression, 1212
Leigh JS Jr. *See* Renshaw PF
Lelord G. *See* Martineau J
Lemus CZ, Asnis GM, Eisenberg J, Halbreich U, van Praag HM, Zukin SR. Imipramine binding and cortisol in depression, 1440-le
Lerbinger J. *See* Bond TC
Lesser J. *See* Lazarus LW
Leventhal BL. *See* Cook EH
Levin R, Leaton EM, Lee SI. The value of nasopharyngeal recording in psychiatric patients, 1236
Levine AS. *See* Hatsukami DK
Levine AS. *See* Mitchell JE
Levinson DF. *See* Schmidt K
Lewitt M. *See* Schmidt K
Lewy AJ. *See* Sack RL
Libet B. *See* Kaitin KI
Lieberman KW. *See* Sechzer JA
Lindback T. *See* Reichelt KL
Linnoila M. *See* Adinoff B
Linnoila M. *See* Kaufmann CA
Linnoila M. *See* Roy A
Linnoila M. *See* Roy-Byrne PP
Linnoila M. *See* Siever LJ
Livesey JH. *See* Joyce PR
Lofthouse R. *See* Roberts GW
Lohr JB, Jeste DV. Cerebellar pathology in schizophrenia? A neuronometric study, 865
London E, de Leon MJ, George AE, Englund E, Ferris S, Gentes C, Resiberg B. Periventricular lucencies in the CT scans of aged and demented patients, 960
Lôo H. *See* Galzin AM
Lôo H, Dennis T, Vanelle JM, Rouquier L, Poirier-Littré MF, Garreau M, Benkelfat C, Sechter D, Scatton B. Lack of correlation between plasma DOPEG and urinary MOPEG levels in depressed patients, 900
Loosen PT. *See* Hsiao JK
Lovett L, Watkins SE, Shaw DM. The use of alternative drug therapy in nine patients with recurrent affective disorder resistant to conventional prophylaxis, 1344
Lukács H. *See* Magyar I
Lynch MR, Carey RJ. Within-session data, 573-le

Maas JW. *See* Secunda SK
Maes JM. *See* Charles GA
Magyar I, Lukács H, Mód L, Alföldi A, Arató M. Military induction, stress, and DST, 1102-le
Mahler E. *See* Csernansky JG
Maj M. *See* Monteleone P
Majchrowicz E. *See* Adinoff B
Malek-Ahmadi P. *See* McMahon T
Malenka RC, Angel RW, Thiemann S, Weitz CJ, Berger PA. Central error-correcting behavior in schizophrenia and depression, 263
Malitz S. *See* Steif BL
Mamelak M. *See* Williamson PC
Manschreck TC. *See* Pollack MH
Marcie P. *See* Guenther W
Marder SR. *See* Irwin M
Marquis JK. *See* Zubenko GS
Marriott PF. *See* McIntyre IM
Martin B. *See* Naylor GJ
Martin JB. *See* Black PM
Martin PR. *See* Adinoff B
Martineau J, Barthelemy C, Lelord G. Long-term effects of combined vitamin B_6-magnesium administration in an autistic child, 511
Masana J. *See* Obiols JE
Mason GA. *See* Hsiao JK
Mathé AA, Eberhard G, Sääf J, Wetterberg L. Plasma prostaglandin E_2 metabolite—measured as 11-deoxy-15-keto-13,14-dihydro-11β,16ε-cyclo-PGE_2—in twins with schizophrenic disorder, 1024
Mathew RJ. Regional cerebral blood flow in homosexual men, 1109-le
Mathew RJ, Wilson WH, Tant SR. Determinants of resting regional cerebral blood flow in normal subjects, 907
Matsue Y, Okuma T, Saito H, Aneha S, Ueno T, Chiba H, Matsuoka H. Saccadic eye movements in tracking, fixation, and rest in schizophrenic and normal subjects, 382
Matsunaga H. *See* Sarai M

Matsuoka H. *See* Matsue Y
McAmis B. *See* Cohen MR
McCauley RB. *See* Oxenkrug GF
McClenahan KL. *See* Roth WT
McCue RE. *See* Georgotas A
McDaniel KD. *See* Stone JL
McIntosh S. *See* Riddle MA
McIntyre IM. *See* Oxenkrug GF
McIntyre IM, Marriott PF, Jefferys D, Burrows GD, Judd FK, Norman TR. Melatonin in panic disorder, 1438-le
McLeod DR, Hoehn-Saric R, Stefan RL. Somatic symptoms of anxiety: comparison of self-report and physiological measures, 301
McMahon T, Malek-Ahmadi P, Ainslie J. DST in chronic schizophrenia, 570-le
Meares R. *See* Gordon E
Mellentin JD. *See* Csernansky JG
Meltzer HL. Lithium mechanisms in bipolar illness and altered intracellular calcium functions, 492
Mendlewicz J. *See* Egrise D
Mendlewicz J. *See* Kerhofs M
Merriam AE. Kleine-Levin syndrome following acute viral encephalitis, 1301
Merrin EL, Fein G, Floyd TC, Yingling CD. EEG asymmetry in schizophrenic patients before and during neuroleptic treatment, 455
Meunier JC. *See* Charles G
Miewald BK. *See* Cornelius JR
Mifune K. *See* Hayashida Y
Milici N. *See* Kemali M
Miller GA. Information processing deficits in anhedonia and perceptual aberration: a psychophysiological analysis, 100
Miller LS. *See* Sack RL
Minkoff JR. *See* Peabody CA
Mirel J. *See* Charles G
Missa JN. *See* Kerkhofs M
Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C. Decreased serotonin S_2 and increased dopamine D_2 receptors in chronic schizophrenics, 1407
Mitani Y. *See* Hayashida Y
Mitchell JE. *See* Hatsukami DK
Mitchell JE, Laine DE, Morley JE, Levine AS. Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome, 1399
Mizoi Y. *See* Mita T
Mód L. See Magyar I
Mokrusch T, Ulrich P. Classics in biological psychiatry? 585-ed
Monteleone P, Maj M, Iovino M, Steardo L. Growth hormone response to sodium valproate in chronic schizophrenia, 588
Monti JA. *See* Smythies JR
Mooney NA, Cooke ED, Bowcock SA, Hunt SA, Timmons BH. Hyperventilation is associated with a redistribution of peripheral blood lymphocytes, 1324
Moreau F. *See* Conri C
Morere D. *See* Smythies JR
Morgan SF. *See* Hatsukami DK
Morganti A. *See* Altamura AC
Morley JE. *See* Hatsukami DK
Morley JE. *See* Mitchell JE
Morris H. *See* Carr V
Moser E. *See* Guenther W
Motega Y. *See* Tada K
Moulthrop MA. *See* Rose RP
Mueller EA. *See* Newhouse PA
Mueller-Spahn F. *See* Guenther W
Mukundan CR. Computed EEG in schizophrenics, 1225
Mukundan CR. Middle latency components of evoked potential responses in schizophrenics, 1097
Mukundan CR, Jaswinder S, Ray R, Nimesh GD. Bereitschaftspotential in alcoholics, 1090
Müller OA. *See* Holsboer F
Murphy DL. *See* Newhouse PA
Murphy DL. *See* Siever LJ
Murphy ST. *See* Cameron O

Nadaud D. *See* Stinus L
Nagase T. *See* Tada K
Nagashima A. *See* Tada K
Nair NPV, Hariharasubramanian N, Pilapil C, Isaac I, Thavundayil JX. Plasma melatonin—an index of brain aging in humans? 141
Nair V. *See* Yassa R
Nakai H. *See* Mita T
Naor S. *See* Halbreich U
Nasrallah HA, Andreasen NC, Coffman JA, Olson SC, Dunn VD, Ehrhardt JC, Chapman SM. A controlled magnetic resonance imaging study of corpus callosum thickness in schizophrenia, 274
Nawara C. *See* Schlemmer RF Jr
Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis, 915
Nemes ZC, Volavka J, Cooper TB, O'Donnell J, Jaeger J. Lithium and haloperidol, 568-le
Newhouse PA, Sunderland T, Tariot PN, Mueller EA, Murphy DL, Cohen RM. Prolactin response to TRH in Alzheimer's disease and elderly controls, 963
Nicholls MG. *See* Joyce PR
Nimesh GD. *See* Mukundan CR

Nino-Murcia G. *See* Kaitin KI
Nino-Murcia G. *See* Welsh DK
Nishimon K. *See* Sora I
Nishino N. *See* Mita T
Nishiwaki S. *See* Kiriike N
Nixon RA. *See* Zubenko GS
Nogami Y. *See* Tada K
Nomoto M. *See* Izumi K
Norman TR. *See* McIntyre IM
Novak EA. *See* Hryhorczuk LM
Nurnberger JI Jr. *See* Berrettini WH
Nurnberger JI Jr, Kessler L, Simmons-Alling S, Gershon ES. Pirbuterol trial as antidepressant, 565-le

Obiols JE, Bachs JS, Masana J. Event-related potentials in young chronic schizophrenics, 856
O'Donnell J. *See* Nemes ZC
Ogawa T. *See* Kashihara K
Okuma T. *See* Matsue Y
Olson SC. *See* Nasrallah HA
Otsuki S. *See* Kashihara K
Otsuki S. *See* Sora I
Overstreet DH. Selective breeding for increased cholinergic function: development of a new animal model of depression, 49
Overstreet DH, Janowsky DS, Gillin JC, Shiromani PJ, Sutin EL. Stress-induced immobility in rats with cholinergic supersensitivity, 657
Oxenkrug GF, McIntyre IM, Balon R, Jain AK, Appel D, McCauley RB. Single dose of tranylcypromine increases human plasma melatonin, 1085

Pandey G. *See* Lazarus LW
Patou G, Crow TJ, Taylor GR. The effects of psychotropic drugs on synthesis of DNA and the infectivity of herpes simplex virus, 1221
Peabody CA. *See* Warner MD
Peabody CA, Minkoff JR, Davies HD, Winograd CH, Yesavage J, Tinklenberg JR. Thyrotropin-releasing hormone stimulation test and Alzheimer's disease, 553
Perényi A. *See* Faludi G
Peroutka SJ. *See* Tecott LH
Pfefferbaum A. *See* Roth WT
Pfohl B. *See* Wysham C
Pfohl B, Coryell W, Stangl D, Zimmerman M. Body weight and reported versus measured weight loss as confounders of the dexamethasone suppression test, 931
Pickar D. *See* Roy A
Pickar D. *See* Wolkowitz OM
Pilapil C. *See* Nair NPV
Pohl R. *See* Bridges M
Poirier-Littré MF. *See* Lôo H
Pollack MH, Manschreck TC. Oculocutaneous albinism and schizophrenia, 830
Pollock V. *See* Schneider LS
Portnoy S. *See* Steif BL
Post RM. *See* Roy-Byrne PP
Post RM. *See* Uhde TW
Prange AJ Jr. *See* Hsiao JK
Preskorn SH. *See* Kent TA
Prosser E. *See* Csernansky JG
Puech AJ. *See* Carnoy P

Ragunath J. *See* Kosten TR
Rainey JM. *See* Bridges M
Rainey JM Jr. *See* Hryhorczuk LM
Raisys V. *See* Khan A
Raitiere MN. Subcortical dysrhythmia and catatonia, 1351-le
Ray R. *See* Mukundan CR
Reichelt KL, Saelid G, Lindback T, Bøler JB. Childhood autism: a complex disorder, 1279
Reisberg B. *See* London E
Renshaw CE. *See* Renshaw PF
Renshaw PF, Summers JJ, Renshaw CE, Hines KG, Leigh JS Jr. Changes in the ^{31}P-NMR spectra of cats receiving lithium chloride systemically, 694
Reveley MA. *See* Kolakowska T
Reynolds CF III. *See* Kupfer DJ
Reynolds CF III. *See* Sewitch DE
Richardson SB. *See* Serby M
Richardson-Carlson R. *See* Kalivas PW
Riddle MA, Anderson GM, McIntosh S, Harcherik DF, Shaywitz BA, Cohen DJ. Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: age and sex effects and individual variability, 69
Riemann D. *See* Höchli D
Ries RK, Wittkowsky AK. Synergistic action of alprazolam with tranylcypromine in drug-resistant atypical depression with panic attacks, 522
Risch SC. *See* Atkinson JH Jr
Rivinus TM. *See* Biederman J
Roberts GW, Colter N, Lofthouse R, Bogerts B, Zech M, Crow TJ. Gliosis in schizophrenia: a survey, 1043
Robertson MM, Coppen A, Trimble MR. The dexamethasone suppression test in medicated epileptic patients, 225
Robins E. Psychosis and suicide, 665
Roffwarg HP. *See* Giles DE
Rondot P. *See* Guenther W
Rose G. *See* Adler LE

Rose RP, Moulthrop MA. Differential responsivity of verbal and visual recognition memory to physostigmine and ACTH, 538
Ross CA. Biological tests for mental illness: their use and misuse, 431-ed
Roth WT, Telch MJ, Taylor CB, Sachitano JA, Gallen CC, Kopell ML, McClenahan KL, Agras WS, Pfefferbaum A. Autonomic characteristics of agoraphobia with panic attacks, 1133
Rothke S, Bush D. Neuropsychological sequelae of neuroleptic malignant syndrome, 838
Rothschild AJ. *See* Bond TC
Rotrosen J. *See* Fiedler P
Rotrosen JP. *See* Serby M
Rouquier L. *See* Lôo H
Rowe WT. *See* Vieweg WVR
Roy A, Linnoila M, Karoum F, Pickar D. Urinary excretion of free tyramine and of norepinephrine and its metabolites in unipolar depressed patients, 221
Roy-Byrne PP, Uhde TW, Sack DA, Linnoila M, Post RM. Plasma HVA and anxiety in patients with panic disorder, 849
Rubin RT. More on DST, 236-le
Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness, 341
Rubinstein M. *See* Egrise D
Rush AJ. *See* Giles DE
Rypma B. *See* Serby M

Sääf J. *See* Mathé AA
Sachitano JA. *See* Roth WT
Sack DA. *See* Roy-Byrne PP
Sack RL, Lewy AJ. Desmethylimipramine treatment increases melatonin production in humans, 406
Sack RL, Lewy AJ, Miller LS, Singer CM. Effects of morning versus evening bright light exposure on REM latency, 410
Sackeim HA. *See* Steif BL
Saelid G. *See* Reichelt KL
Sailer V. *See* Cohen MR
Saito H. *See* Matsue Y
Sandyk R. ECT, opioids, and motility in Parkinson's disease, 428-le
Sandyk R. ECT, opioid system, and motor response in Parkinson's disease, 235-le
Sandyk R. Parkinsonism induced by diazepam, 1232-le
Sangal R. Electroconvulsive treatment: a rose is a rose, 709-ed
Sarai M, Matsunaga H. Low-dose (0.5-mg) dexamethasone suppression test in depressive patients, 744
Saran AS. *See* Addy RO
Sato M. *See* Kashihara K
Scatton B. *See* Lôo H
Schatzberg AF. *See* Bond TC
Schefold L. *See* Krüger R
Schiebe M. *See* Born J
Schildkraut JJ. *See* Biederman J
Schildkraut JJ. *See* Bloomingdale KL
Schlemmer RF Jr, Nawara C, Heinze WJ, Davis JM, Advokat C. Influence of environmental context on tolerance to LSD-induced behavior in primates, 314
Schlesser MA. *See* Giles DE
Schmidt K, Delaney MA, Jensen M, Levinson DF, Lewitt M. Methylphenidate challenge in a manic boy, 1107-le
Schneider LS, Severson JA, Pollock V, Cowan RP, Sloane RB. Platelet monoamine oxidase activity in elderly depressed outpatients, 1360
Schoutens A. *See* Egrise D
Schubert DSP. *See* Addy RO
Schulz SC. *See* Cornelius JR
Schwartz G. *See* Yassa R
Sechter D. *See* Galzin AM
Sechter D. *See* Lôo H
Sechzer JA, Lieberman KW, Alexander GJ, Weidman D, Stokes PE. Aberrant parenting and delayed offspring development in rats exposed to lithium, 1258
Secunda SK, Cross CK, Koslow S, Katz MM, Kocsis J, Maas JW, Landis H. Biochemistry and suicidal behavior in depressed patients, 756
Seno H. *See* Endo M
Serby M, Richardson SB, Rypma B, Twente S, Rotrosen JP. Somatostatin regulation of the CRF-ACTH-cortisol axis, 971
Sethi BB, Trivedi JK, Kumar P, Gulati A, Agarwal AK, Sethi N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors, 3
Sethi N. *See* Sethi BB
Severson JA. *See* Schneider LS
Sewitch DE, Kupfer DJ, Reynolds CF III. Alpha-NREM sleep distributed across the 24-hour day in a legally blind elderly male, 201
Sharp RR. *See* Ballast CL
Shaw DM. *See* Lovett L
Shaw NA. The effect of electroconvulsive shock on the brain stem auditory evoked potential in the rat, 1327
Shaywitz BA. *See* Riddle MA
Sheehan DV. *See* Surman OS
Shelton RC. *See* Grebb JA
Shelton RC. *See* Kaufmann CA
Shimizu T. *See* Izumi K
Shiromani PJ. *See* Overstreet DH
Siever LJ. *See* Uhde TW

Siever LJ, van Kammen DP, Linnoila M, Alterman I, Hare T, Murphy DL. Smooth pursuit eye movement disorder and its psychobiologic correlates in unmedicated schizophrenics, 1167
Simmons-Alling S. *See* Berrettini WH
Simmons-Alling S. *See* Nurnberger JI Jr
Simon P. *See* Carnoy P
Simon P. *See* Frances H
Simonoff M. *See* Conri C
Simson PG, Weiss JM, Ambrose MJ, Webster A. Infusion of a monoamine oxidase inhibitor into the locus coeruleus can prevent stress-induced behavioral depression, 724
Singer CM. *See* Sack RL
Sloane RB. *See* Schneider LS
Smith RC. Studying the meaning of dreams: accurate definition of the independent variable, 989
Smythies JR, Alarcon RD, Morere D, Monti JA, Steele M, Tolbert LC, Walter-Ryan WG. Abnormalities of one-carbon metabolism in psychiatric disorders: study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes, 1391
Snider RM. *See* Dilsaver SC
Soloff PH. *See* Cornelius JR
Sonoda H. *See* Izumi K
Sora I, Nishimon K, Otsuki S. Dexamethasone suppression test and noradrenergic function in affective and schizophrenic disorders, 621
Soubrie P. *See* Carnoy P
Spradin WW. *See* Vieweg WVR
Stalla GK. *See* Holsboer F
Stangl D. *See* Pfohl B
St Clair DM. *See* Blackwood DHR
Steardo L. *See* Monteleone P
Steele M. *See* Smythies JR
Stefan RL. *See* McLeod DR
Steif BL, Sackeim HA, Portnoy S, Decina P, Malitz S. Effects of depression and ECT on anterograde memory, 921
Steiner W. *See* Chouinard G
Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports, 1067
Stevens JR. Left hemisphere in schizophrenia, 1230-le
Stinus L, Nadaud D, Jauregui J, Kelley AE. Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nucleus accumbens, 34
Stokes PE. *See* Sechzer JA
Stone JL, McDaniel KD, Hughes JR, Hermann BP. Episodic dyscontrol disorder and paroxysmal EEG abnormalities: successful treatment with carbamazepine, 208
Strom TB. *See* Surman OS
Sulon J. *See* Charles G
Summers JJ. *See* Renshaw PF
Sunderland T. *See* Newhouse PA
Surman OS, Williams J, Sheehan DV, Strom TB, Jones KJ, Coleman J. Immunological response to stress in agoraphobia and panic attacks, 768
Sutin EL. *See* Overstreet DH
Swerdlow NR. *See* Downs NS
Swerdlow NR, Braff DL, Geyer MA, Koob FG. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics, 23

Tachiki KH, Buckman TD, Eiduson S, Kling AS, Hullett J. Phosphatidylserine inhibition of monoamine oxidase in platelets of schizophrenics, 59
Tada K, Nogami Y, Nagashima M, Nagase T, Ishiwata H, Motegi Y, Ikeda M. Trace elements in the hair of schizophrenics, 325
Tanaka C. *See* Mita T
Tant SR. *See* Mathew RJ
Tariot PN. *See* Newhouse PA
Taylor CB. *See* Roth WT
Taylor EH. *See* Grebb JA
Taylor GR. *See* Patou G
Tecott LH, Kwong LL, Uhr S, Peroutka SJ. Differential modulation of dopamine D_2 receptors by chronic haloperidol, nitrendipine, and pimozide, 1114
Telch MJ. *See* Roth WT
Thavundayil JX. *See* Nair NPV
Thiemann S. *See* Malenka RC
Thienhaus OJ, Cliffe C, Zemlan FP, Bosmann HB. Superoxide dismutase, chromosome 21, and Alzheimer's disease, 1106-le
Thomas DR. DST, depression, and anxiety, 427-le
Thomas DR. T_3 and T_4 in unipolar depression, 576-le
Thomas DR, Harris B, Cook N. Postdexamethasone cortisol levels, weight loss, and aging, 575-le
Timmons BH. *See* Mooney NA
Tinklenberg JR. *See* Peabody CA
Tinklenberg JR. *See* Warner MD
Tolbert LC. *See* Smythies JR
Tominaga H. *See* Izumi K
Tomita S. *See* Hayashida Y
Trimble MR. *See* Robertson MM
Trivedi JK. *See* Sethi BB
Tseng YT. *See* Chang WH
Tumuluru RV. *See* Cornelius JR
Turnbull GJ. Psychosis and polydipsia, 1439-le
Twente S. *See* Serby M

Ueno T. *See* Matsue Y
Uhde TW. *See* Roy-Byrne PP
Uhde TW, Vittone BJ, Siever LJ, Kaye WH, Post RM. Blunted growth hormone response to clonidine in panic disorder patients, 1081
Uhr S. *See* Tecott LH
Ulrich P. *See* Mokrusch T
Ulrich RF. *See* Kupfer DJ

Vanelle JM. *See* Lôo H
Van Haren J, Fontaine R. EEG seizures without physical signs, 1105-le
van Kammen DP. *See* Siever LJ
Van Orden G. *See* Kalivas PW
van Praag HM. *See* Lemus CZ
van Praag HM. Biological suicide research: outcome and limitations, 1305
van Praag HM. Psychiatrists, beware of dichotomies, 247-ed
Van Sweden B. Disturbed vigilance in mania, 311
Vasile RG. *See* Bloomingdale KL
Vieweg WVR, David JJ, Rowe WT, Yank GR, Spradlin WW. Diurnal variation of urinary excretion for patients with psychosis, intermittent hyponatremia, and polydipsia (PIP syndrome), 1031
Vital-Herne J. *See* Halbreich U
Vittone BJ. *See* Uhde TW
Volavka J. *See* Nemes ZC
Volicer L. *See* Zubenko GS
von Bardeleben U. *See* Holsboer F
von Oefele K. *See* Guenther W

Walter-Ryan WG. *See* Smythies JR
Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR. Olfactory deficits and Alzheimer's disease, 116
Watkins SE. *See* Lovett L
Watson Y. *See* Naylor GJ
Webster A. *See* Simson PG
Weidman D. *See* Sechzer JA
Weiler M. *See* Boutros NN
Weiss JM. *See* Simson PG
Weitz CJ. *See* Malenka RC
Welkowitz J. *See* Georgotas A
Welsh DK, Nino-Murcia G, Gander PH, Keenan S, Dement WC. Regular 48-hour cycling of sleep duration and mood in a 35-year-old woman: use of lithium in time isolation, 527
Wetterberg L. *See* Mathé AA
Williams AO. *See* Kolakowska T
Williams J. *See* Surman OS
Williamson PC, Csima A, Galin H, Mamelak M. Spectral EEG correlates of dream recall, 717
Wilmotte J. *See* Charles G
Wilmotte J. *See* Charles GA
Wilson DWS, Douglass AB. Niacin skin flush is not diagnostic of schizophrenia, 974
Wilson WH. *See* Mathew RJ
Winograd CH. *See* Peabody CA
Wittkowsky AK. *See* Ries RK
Wolkin A. *See* Fiedler P
Wolkowitz OM, Doran AR, Breier A, Cohen MR, Pickar D. Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia, 366
Wortis J.
The medieval garden, 863-ed
Neuropsychiatry of acquired immune deficiency syndrome, 1357-ed
Paranoia and Armageddon, 987-ed
Research support: who's the enemy? 339-ed
Wyatt RJ. *See* Iager AC
Wyatt RJ. *See* Kaufmann CA
Wysham C, Pfohl B, Kathol RG. Arginine vasopression stimulation and imipramine, 1353-le

Yalow RS. Peer review and scientific revolutions, 23-ed
Yamadori T. *See* Mita T
Yamawaki S. *See* Hotta I
Yank GR. *See* Vieweg WVR
Yassa R, Nair V, Schwartz G. Early versus late onset psychosis and tardive dyskinesia, 1291
Yeh EK. *See* Chang WH
Yeragani VK. *See* Bridges M
Yeragani VK, Gershon S. Hammond and lithium: historical update, 1101-le
Yesavage J. *See* Peabody CA
Yingling CD. *See* Merrin EL
Young RC, Alcena V. Serum lithium concentrations and peripheral leukocytes in a case of leukopenia, 1072
Yuwiler A. *See* Irwin M

Zanchetti A. *See* Altamura AC
Zech M. *See* Roberts GW
Zemlan FP. *See* Hirschowitz J
Zemlan FP. *See* Thienhaus OJ
Zimmerman M. *See* Pfohl B
Zubenko GS, Marquis JK, Volicer L, Direnfeld LK, Langlais PJ, Nixon RA. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study, 1365
Zubin J. Spontaneous improvement, vulnerability, and placebos, 1235-ed
Zukin SR. *See* Lemus CZ
Zulley J. *See* Höchli D

Subject Index to Volume 21

Acoustic startle response, 23
Acquired immune deficiency syndrome, 1357-ed
  encephalitis, mimicking alcohol dementia and depression, 394
Adrenocorticotrophic hormone, 124
Aging, 575-le
  and plasma melatonin, 141
Agoraphobia, 768, 1133
Alcoholics
  bereitschaftspotential in, 1090
  prostaglandin activity in, 1347
Alpha-NREM sleep, 201
Alprazolam
  with tranylcypromine, 522
Alzheimer's disease
  cerebrospinal fluid analysis, 1365
  olfactory deficits, 116
  and superoxide dismutase, 1106-le
  thyrotropin-releasing hormone, 553, 963
Amitriptyline, 483
Angina
  and L-triiodothyronine, 543
Anhedonia
  information processing deficits, 100
Anorexia nervosa, 213
Antidepressants, 1155
  effect of neuroleptics on, 1247
  withdrawal and paradoxical mood response, 1298
Anxiety, 427-le
  circadian fluctuations in, 567-le
  monoamine oxidase activity in, 847
  somatic symptoms, 301
Apomorphine
  growth hormone response to, 445
  stereotypies, 402
Arginine vasopressin stimulation
  and imipramine, 1353-le
Auditory brain stem responses
  in schizophrenia, 177
Autism
  in childhood, 1279
  and vitamin B_6-magnesium therapy, 511

Barbiturates
  and dexamethasone suppression test, 860-le
Benzodiazepine antagonist
  and ethanol withdrawal, 643
Beta-adrenergic agonist
  effect on 5-hydroxytryptophan receptors, 1075
Biological psychiatry literature, 585-ed
Borderline personality disorder, 560
  and EEG, 977
Brain stem auditory evoked potential, 1327
Bulimia
  and CCK-8, 1399
  and dexamethasone suppression test, 328
  and naloxone, 1399

Cannabis
  antianxiety effect of, 3
Captopril, 1425
Carbamazepine, 208
  and dopaminergic supersensitivity, 238-le
Catatonia
  and subcortical dysrhythmia, 1351-le
Cerebellar vermis atrophy, 705-le
Cerebral blood flow, 907
  during motor function, 889
  in homosexuals, 1109-le
Cerebral membranes
  ^{3}H-imipramine binding, 883
Cerebral microcirculation, 483
Cerebrospinal fluid
  adrenocorticotrophic hormone, 124
  analysis in dementia, 1365
  beta-endorphin concentration, 1077
  gamma-aminobutyric acid, 844
  monoamine metabolite levels, 69
  somatostatin, 341, 1077
Childhood autism, 1279
Childhood hyperactivity
  and zinc, 704-le
Cholecystokinin
  effect in bulimia, 1399
Cholinergic function
  animal model, 49
Cholinergic system supersensitivity, 813
  and stress, 657, 1093

Abbreviations
ed: Editorial
le: Letter to the Editor

Chromosome 21, 1106-le
Clenbuterol, 1075
Clomipramine
and REM sleep suppression, 1217
Clonidine
growth hormone response to, 1081
CORRESPONDENCE
Arginine vasopressin stimulation and imipramine, 1353
Barbiturates and DST, 860
Carbamazepine and dopaminergic supersensitivity, 238
Cholinergic–monoamine systems, depression, and panic, 571
Circadian fluctuations in anxiety disorders, 56
DST and endogeneity, 119
DST, depression, and anxiety (with response), 427
DST, ECT, and prognosis, 1353
DST in chronic schizophrenia, 570
DST in Czechoslovakia, 1103
ECT, opioids, and motility in Parkinson's disease (with response), 428
ECT, opioid system, and motor response in Parkinson's disease, 235
EEG seizures without physical signs, 1105
Effect of lithium on RBC water permeability, 426
Electrophysiology of schizophrenia, 233
Hammond and lithium: historical update, 1101
Hydergine effect on prolactin and reaction time in dementia, 1229
Imipramine binding and cortisol in depression, 1440
Left hemisphere in schizophrenia (with response), 1230
Melatonin in panic disorder, 1438
Methylphenidate challenge in a manic boy, 1107
Military induction, stress, and DST, 1102
More on DST, 236
Parkinsonism induced by diazepam (with response), 1232
Pirbuterol trial as antidepressant, 565
Phosphatidylcholine and tardive dyskinesia (with response), 702
Pituitary function, affective disorder, and cerebellar vermis atrophy, 705
Pituitary function and deep brain structures, 240
Psychosis and polydipsia, 1439
Regional cerebral blood flow in homosexual men, 1109
Subcortical dysrhythmia and catatonia, 1351
Superoxide dismutase, chromosome 21, and Alzheimer's disease, 1106
Triiodothyronines, depression, and fasting (with response), 425
Within-session data, 573
Zinc and childhood hyperactivity, 704
Corticotropin-releasing hormone
in depression, 601
Cortisol, 549, 575-le
and naltrexone treatment, 217
and stages of sleep, 1415

Delirium
and L-5-hydroxytryptophan, 673
Dementia, 557
cerebrospinal fluid analysis, 1365
diagnosis using P300 latency, 1111, 1123
effect of hydergine, 1229-le
periventricular lucencies in CT scans, 960
Depression
alprazolam with tranylcypromine treatment, 522
animal model, 49
captopril treatment, 1425
cerebral blood flow, 889
and cholinergic–monoamine systems, 571-le
corticotropin-releasing hormone in, 601
CSF somatostatin and beta-endorphin, 1077
and dexamethasone suppression test, 236-le, 390, 436, 744, 1008, 1239, 1434
delusional, 1239
effect of mianserin, 1331
efficacy of MAOIs versus tricyclic antidepressants, 1155
in elderly, 699, 1155, 1360
and electroconvulsive therapy, 921
error-correcting behavior, 263
and family history, 1239
growth hormone response to TRH, 595
imipramine binding sites, 1440-le
monoamine oxidase activity in, 390, 847, 1360
and nortriptyline treatment, 1155
and pain, 613
with panic attacks, 522
and phenelzine treatment, 699, 1155
plasma cortisol levels, 1440-le
plasma DOPEG and urinary MOPEG levels, 900
and REM sleep, 189, 465
REM sleep suppression as diagnostic tool, 1217
and serotonin, 842
serum vanadium levels, 1335
sleep EEG in, 229
sleep parameters in, 1340
and suicide, 756
triiodothyronine and thyroxine in, 576-le
tyramine and norepinephrine excretion, 221
and vasopressin–neurophysin, 1212

Desmethylimipramine
and melatonin, 406
Dexamethasone suppression test, 119-le, 735
in anxiety, 427-le
and barbiturates, 860-le
in bulimia, 328
and cortisol, 549, 1434
in Czechoslovakia, 1103-le
in depression, 236-le, 390, 436, 744, 1008, 1239, 1434
and electroconvulsive therapy, 1353-le
in epilepsy, 225
and methylene blue, 968
in panic disorders, 853, 1008
in psychosis, 390
in schizophrenia, 570-le, 621
and stress, 1102-le
and weight loss, 931
Diazepem
and parkinsonism, 1232-le
N, *N*-Dimethyltryptamine metabolism, 84
DNA synthesis
effect of psychotropic drugs on, 1221
Dopamine, 317
and acoustic startle response, 23
depletion, 775
and enkephalin, 939
Dopamine D_2 receptors, 1114
in schizophrenia, 1407
Dreams, 989
recall and EEG correlates, 717

EDITORIALS
Biological tests for mental illness: their use and misuse, 431
Classics in biological psychiatry? 585
Electroconvulsive treatment: a rose is a rose, 709
Fourth world congress of biological psychiatry, 123
The medieval garden, 863
Neuropsychiatry of acquired immune deficiency syndrome, 1357
P300 latency as a biological marker of dementia, 1111
Paranoia and Armageddon, 987
Peer review and scientific revolutions, 1
Psychiatrists, beware of dichotomies, 247
Research support: who's the enemy? 339
Spontaneous improvement, vulnerability, and placebos, 1235
Electroconvulsive therapy, 578-le, 709-ed
and depression, 921
and dexamethasone suppression test, 1353-le
effect on brain stem auditory evoked potential, 1327
and memory, 921
in parkinsonism, 235-le, 428-le
seizures, 1105-le
Electroencephalography
in borderline personality disorder, 977
and carbamazepine treatment, 208
coherence and power measures, 1175
in depression, 228
effects of haloperidol–lithium treatment, 170
and neuroleptic treatment, 455
psychiatric correlates, 94
in schizophrenia, 249, 1225
Encephalitis
and acquired immune deficiency syndrome, 1357-ed
and Kleine–Levin syndrome, 1301
Enkephalin
and dopamine, 939
Epilepsy
and dexamethasone suppression test, 225
Epilepsy, temporal lobe
and REM sleep, 1267
Error-correcting behavior, 263
Erythrocyte membrane
adenosine triphosphate activities, 997
Ethanol withdrawal syndrome, 643
Event-related potentials
in borderline personality disorder, 560
physostigmine effect on, 557
in schizophrenia, 856, 1097

Fibroblasts
superoxide dismutase activity in, 322
Fluoxetine
toxicity with L-tryptophan, 1067

Gamma-aminobutyric acid
in manic-depressive illness, 844
Gliosis
in schizophrenia, 1043
Growth hormone
response to apomorphine and diagnosis, 445
response to TRH in depression, 595
response to valproate in schizophrenia, 588

Haloperidol, 374, 650, 1114
and lithium, 170, 568-le
withdrawal symptoms, 398
Herpes simplex virus
and psychotropic drugs, 1221
Homosexuals
and cerebral blood flow, 1109-le
Homovanillic acid
effect of haloperidol on, 374, 422
in panic disorder, 849

Hydergine
effect on prolactin in dementia, 1229-le
L-5-Hydroxytryptophan, 673
Hyperactivity
and limbic dopamine levels, 317
Hyperventilation
and blood lymphocytes, 1324

Imipramine
and arginine vasopressin stimulation, 1353-le
^{3}H-Imipramine binding, 283, 876, 883

Kleine–Levin syndrome
and encephalitis, 1301

Leukemia
CSF monoamine metabolite levels, 69
Leukopenia
and lithium, 677, 1072
Ligand binding, 883
Lithium
and changes in ^{31}P-NMR spectra, 694
effect on 5 HT_1 receptors, 1382
effect on rat behavior and offspring, 1258
effect on RBC water permeability, 426-le
effect on sleep and mood cycle, 527
and haloperidol, 170, 568-le
historical update, 1101-le
and intracellular calcium functions, 492
and leukopenia, 677, 1072
and thyroid dysfunction, 414
toxicity with thioridazine, 835
Lysergic acid diethylamide
retinal changes, 981
tolerance to, 315

Magnetic resonance imaging, 274
Mania, acute
remoxipride treatment, 1429
Manic-depressive illness
ATPase activities in erythrocyte membranes, 997
CSF gamma-aminobutyric acid, 844
and disturbed vigilance, 311
effect of methylene blue in, 915
Meclofenoxate
and tardive dyskinesia, 151
Medicinal herbs, 863-ed
Melatonin
and brain aging, 141
effect of desmethylimipramine on, 406
effect of tranylcypromine on, 1085
in panic disorder, 1438-le
and retinal changes, 981
Memory
depression and electroconvulsive therapy, 921
effect of ACTH on, 538
effect of physostigmine on, 538, 557
Mental illness
use and misuse of biological tests, 431-ed
Methylene blue, 915, 968
Methylphenidate, 1015, 1107-le
Mianserin
effect on plasma renin, 1331
Monoamine oxidase
activity in anxiety, 847
activity in depression, 390, 847, 1360
inhibitors, 59, 724, 1085, 1155

Naloxone, 1399
Naltrexone, 217, 293
Nasopharyngeal recording, 1236
Neuroleptic malignant syndrome, 838
Neuroleptics, 34
and EEG asymmetry, 455
effect on tricyclic antidepressants, 1247
withdrawal, 398
Niacin skin flush, 974, 1347
Nitrendipine, 1114
Nortriptyline, 1155

Oculocutaneous albinism
and schizophrenia, 830
One-carbon metabolism, 1391

Pain
and depression, 613
Panic disorder
and agoraphobia, 1133
and depression, 571-le
and dexamethasone suppression test, 1008
growth hormone response to clonidine in, 1081
immunological response to stress in, 768
and melatonin, 1438-le
and plasma homovanillic acid, 849
Paraneoplastic encephalopathy, 686
Paranoia, 987-ed
and prolactin, 632
Parkinsonism
cerebrospinal fluid analysis, 1365
diazepam-induced, 1232-le
electroconvulsive therapy in, 235-le, 428-le
Phenelzine, 1155
in geriatric depression, 699
Phosphatidylcholine
and tardive dyskinesia, 702-le
Phosphatidylserine, 59

Physostigmine
effect on memory, 539, 557
endocrine response to, 775
Pimozide, 1114
PIP syndrome, 1031
Pirbuterol, 565-le
Pituitary function
and deep brain structures, 240-le
Prefrontal cortex
and antipsychotic action of haloperidol, 422
Prolactin
effect of hydergine on, 1229-le
and paranoia, 632
response to TRH, 963
Prostaglandin activity
in alcoholics, 1347
in schizophrenia, 1347
Prostaglandin E_2 metabolite
in schizophrenia, 1025
Psychiatric disorders
CSF somatostatin, 341
and encephalography, 94, 1175
mimicked by AIDS encephalitis, 394
one-carbon metabolism in, 1391
Psychogenic polydipsia, 577-le
Psychosis
information processing deficits, 100
and polydipsia, 1439-le
and serine metabolism, 951
and suicide, 665
and tardive dyskinesia, 1291
Psychotropic drugs
effect on DNA, 1221

Rapid eye movement latency
effect of bright light exposure on, 410
and endogenous depressive symptoms, 473
Rapid eye movement sleep
in depression, 189, 465
and interictal epileptic activity, 1267
suppression by clomipramine, 1217
Remoxipride, 1429
Research support, 339-ed
Ro 15-1788, 643

Schizophrenia
and abnormal involuntary movement, 751
auditory brain stem responses, 177
and bromocriptine, 519
cerebellar pathology, 865
cerebral blood flow, 889
corpus callosum thickness, 274
and dexamethasone suppression test, 570-le, 621
dopamine D_2 receptors, 1407
and electroencephalography, 455, 1225
electrophysiology of, 233-le
endogenous opioid regulation in, 366
error-correcting behavior, 263
and event-related potentials, 856, 1097
genetics of, 1051, 1189
gliosis in 1043
growth hormone response to valproate in, 588
hair trace elements in, 325
left hemisphere dysfunction, 249, 1230-le
and niacin skin flush, 974, 1347
noradrenergic function in, 623
and oculocutaneous albinism, 830
plasma prostaglandin E_2 metabolite in, 1024
and platelet monoamine oxidase inhibition, 59
and prostaglandin activity, 1347
saccadic eye movements in, 382
serotonin S_2 receptors, 1407
and smooth pursuit eye movement disorder, 1167
superoxide dismutase activity in fibroblasts, 322
and tardive dyskinesia, 161, 751
and verapamil, 691
Sensory gating
effect of drugs on, 787
Serotonin
and depression, 842
platelet uptake, 283
Serotonin receptors, 1407
Sleep
and depression, 1340
disturbance by electrical stimulation of locus coeruleus, 710
and plasma cortisol secretion, 1415
Sleep duration
and mood cycles, 527
Smooth pursuit eye movement disorder, 1167
Somatostatin, 341, 971
Spontaneous improvement, 1235-ed
Stress
and cholinergic system supersensitivity, 657, 1093
and dexamethasone suppression test, 1102-le
Subcortical dysrhythmia
and catatonia, 1351-le
Suicide
biological research, 1305
and depression, 756
and psychosis, 665
Superoxide dismutase
and Alzheimer's disease, 1106-le

Tardive dyskinesia
and meclofenoxate therapy, 151
noradrenergic and neuroradiological abnormalities in, 799
and phosphatidylcholine, 702-le
and prolactin levels, 632
and psychosis, 1291
and schizophrenia, 161, 751
Tetrabenazine, 483
Thyroid dysfunction
lithium-induced, 414
Thyrotropin-binding inhibiting immunoglobulins, 414
Thyrotropin-releasing hormone
and depression, 595
prolactin response to, 963
stimulation test, 417, 553
Thyroxine
and depression, 576-le
Tranylcypromine
effect on human plasma melatonin, 1085
Triiodothyronine
and depression, 425-le, 576-le
L-Triiodothyronine
and angina, 543
L-Tryptophan
toxicity with fluoxetine, 1067

Valproate, 588
Vanadium, 1335
Vasopressin–neurophysin
and depression, 1212
Verapamil, 691

Weight loss
and postdexamethasone cortisol levels, 575-le
Within-session data, 575-le

Zinc
and childhood hyperactivity, 704-le